Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.
Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Vigil Neuroscience. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.
Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and Dana Farber’s Binney Street Capital advisory board. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.
Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.
What is Bruce Booth's net worth?
The estimated net worth of Bruce Booth is at least $29.41 million as of July 9th, 2024. Dr. Booth owns 723,246 shares of Kymera Therapeutics stock worth more than $29,407,182 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Booth may own. Additionally, Dr. Booth receives an annual salary of $75,000.00 as Director at Kymera Therapeutics. Learn More about Bruce Booth's net worth.
How old is Bruce Booth?
Dr. Booth is currently 50 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics is Ms. Ellen V. Chiniara Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 65 years old. Learn More on Bruce Booth's age.
What is Bruce Booth's salary?
As the Director of Kymera Therapeutics, Inc., Dr. Booth earns $75,000.00 per year. There are 4 executives that earn more than Dr. Booth. The highest earning executive at Kymera Therapeutics is Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Bruce Booth's salary.
How do I contact Bruce Booth?
Has Bruce Booth been buying or selling shares of Kymera Therapeutics?
Bruce Booth has not been actively trading shares of Kymera Therapeutics within the last three months. Most recently, Bruce Booth sold 453,960 shares of the business's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a transaction totalling $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares of the company's stock, valued at $27,635,229.66. Learn More on Bruce Booth's trading history.
Who are Kymera Therapeutics' active insiders?
Are insiders buying or selling shares of Kymera Therapeutics?
In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company.
Learn More about insider trades at Kymera Therapeutics. Information on this page was last updated on 9/17/2024.
